Skip to main content
FDA Updates, PARP Inhibitors
A Review of PARP Inhibitors in Clinical Development
Sarah Hopps, PharmD, Carla D. Kurkjian, MD, Shubham Pant, MD
Read More
From the Literature, From the Literature
Bevacizumab Delays Progression in Women with Advanced Ovarian Cancer
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
Read More
From the Literature, From the Literature
Combination Therapy with Pertuzumab Offers New Option in Metastatic Breast Cancer
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
Read More
From the Literature, From the Literature
Chemotherapy-Induced Changes in Brain Structure Correlate with Cognitive Dysfunction
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
Read More
From the Literature, From the Literature
BRAF Inhibitor Therapy Linked to Squamous-Cell Carcinoma in Patients with RAS Mutations
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
Read More
From the Literature, From the Literature
Adding Bevacizumab to Neoadjuvant Chemotherapy Improves Complete Response Rates in Patients with Breast Cancer
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
Read More
Online First
Advances in the Treatment of Multiple Myeloma: Next-Generation Proteasome Inhibition
Alice Goodman
Read More
Online First
The Emerging Role of Carfilzomib in Multiple Myeloma
Kim Redic, PharmD, BCPS
Read More
Online First
Carfilzomib: A New Agent in the Treatment Armamentarium for Multiple Myeloma
Beth Faiman, PhD, APRN-BC, AOCN
Read More
Online First
Stakeholder’s Perspective: Physician
Jeffrey A. Meyerhardt MD, MPH
Read More
Page 190 of 198
Results 1891 - 1900 of 1975